



Medabon® for Medical Abortion: Resource Materials for Health Care Providers and Program Managers

Medabon® contains two medicines—mifepristone and misoprostol—that are widely used for medical abortion. Mifepristone is registered in more than 40 countries for medical abortion and is generally used in combination with misoprostol. Although misoprostol is registered only in a limited number of countries for medical abortion, it is often used for this purpose at the discretion of a physician, something known as off-label use. Medabon® is the first product to package the two medicines together and to be licensed as a combination product. The Medabon® regimen is based on data from large multinational clinical trials undertaken by the World Health Organization (WHO) and is consistent with guidance from WHO and the Royal College of Obstetricians and Gynecologists in the United Kingdom on safe and effective medical abortion.

Concept Foundation, in collaboration with governments and national and international nongovernmental organizations, is preparing for the introduction of Medabon® into health systems in various countries to make it a viable choice for women. Settings with weak health services and scarce resources demonstrate the greatest need for safe abortion services and also face the greatest challenges. Effort is required to prepare health systems and communities to accept and utilize this new health product.

Concept Foundation, Ipas, and PATH have developed this set of materials as a guide for health care providers and program managers who are working to introduce Medabon® in their local contexts. The materials are also intended to serve a wide variety of audiences, including policymakers, the media, and women who choose to use Medabon®. Resource materials in this packet include:

- Medical and Service Delivery Guidelines.
- Medical Guidelines for Providers of Emergency Care.
- What You Need to Know (sample brochure for women).
- Key Talking Points.
- Frequently Asked Questions.
- Selected References.
- Selected Illustrations for Low-Literacy Audiences.
- Adapting Medabon® Materials for Local Use.
- A Framework for Introduction.

The materials in this package represent a consensus view of these organizations specific to the Medabon® product that may differ from their own published protocols for medical abortion in general. Adaptation of some documents may also be required for alignment with local protocols and guidelines (see “Adapting Medabon® Materials for Local Use” for more information). These materials may be adapted and distributed for nonprofit or educational purposes without obtaining permission. Please credit the Concept Foundation, Ipas, and PATH as the source of these materials.

Several organizations worldwide are working on access to safe abortion, including medical abortion. Their expert review and technical materials helped to inform this packet, and special thanks go to the following individuals for their input: Indira Basnett, Marge Berer, Kelly Blanchard, Paul Blumenthal, Peter Fajans, Mary Fjerstad, Shireen Jejeebhoy, Shveta Kalyanwala, Meera Ojha, Melanie Peña, Swaraj Rajbhandari, Paul Van Look, and Beverly Winikoff. These materials were made possible by generous support to PATH from the William and Flora Hewlett Foundation. The documents in *Emergency Contraceptive Pills: A Resource Packet for Health Care Providers and Programme Managers*, developed by the Consortium for Emergency Contraception, helped to provide a framework for this project.

To download electronic copies of these materials, please visit www.medabon.info. To request hard copies, please contact Concept Foundation at medabon@conceptfoundation.org.